• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    D

    Deutsche Gesellschaft für Muskelkranke

    EST. 1965
    59论文总数
    245引用总数

    论文量&引用量时间轴

    机构学者

    论文(59)

    年份
    起
    –
    止
    排序
    1Shared Governance of International Myositis Networks.
    Teerin Liewluck, Lisa G Rider, Karen Cheng,Hector Chinoy,Mazen M Dimachkie, Eduardo Dourado,Prateek C Gandiga, David A Isenberg,Kaveh Ardalan, Shiri Keret,Susan Kim,Peter Korsten,
    2026Clinical and experimental rheumatology(2026)
    引用
    AI阅读
    加入学术空间
    2Reiseimpfungen – Hinweise Und Empfehlungen
    Camilla Rothe,Deike Rosenbusch, Silja Bühler, Torsten Feldt, Markus Frühwein,Martin P. Grobusch, Sabine Jordan,Annette Kapaun,Carsten Köhler, Christina Kreuzberg, Micha Löbermann, Andreas Müller,

    Zusammenfassung Der Ständige Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit (DTG) gibt jährlich Empfehlungen zu Reiseimpfungen. Diese Empfehlungen werden von unabhängigen Experten erstellt. Sie umfassen international verpflichtende sowie länderspezifische und gefährdungsbasierte Impfstrategien. Sie dienen als Entscheidungshilfe für medizinisches Fachpersonal und berücksichtigen Empfehlungen u. a. der WHO, des ECDC, der STIKO und nationaler Gesundheitsbehörden.

    2026Flugmedizin · Tropenmedizin · Reisemedizin - FTR(2026)
    引用
    AI阅读
    加入学术空间
    36Th Global Conference on Myositis (GCOM).
    Anneke Van Der Kooi,Jens Schmidt, Silke Schlüter, 2-2 March , Lisbon, Portugal
    2026Clinical and experimental rheumatology(2026)
    引用
    AI阅读
    加入学术空间
    4Treatment Evolution in Spinal Muscular Atrophy: Insights from the SMArtCARE Registry
    Cornelia Voigt-Müller, Michelle Pfaffenlehner,Günther Bernert,Hakan Cetin,Tim Hagenacker, Heike Kölbel,Hanns Lochmüller, Christian Pfeuffer,Katharina Vill,Maggie C Walter,Janbernd Kirschner,Astrid Pechmann,

    Real-world treatments for 5q-spinal muscular atrophy (SMA) have evolved rapidly following the sequential approval of three disease-modifying treatments (DMTs): nusinersen, onasemnogene abeparvovec and risdiplam. The aim of this study was to map the sequence and timing of SMA treatments accurately using the SMArtCARE registry, a disease-specific registry for patients with SMA across 84 participating centres in Germany, Austria and Switzerland. All patients registered in SMArtCARE were included in the analysis. Patients were grouped based on their treatment regimen: those who remained on the first DMT versus those who switched DMT. The impacts of clinical and genetic factors on treatment decisions were evaluated, including age at initiation of treatment, SMN2 copy number, motor function status, the need for ventilator support or tube feeding, and the presence of scoliosis. A total of 2140 patients were included. Of these, 1294 patients (60.5%) initiated treatment with nusinersen, 514 patients (24.0%) with risdiplam and 243 patients (11.4%) with onasemnogene abeparvovec. Overall, 1366 patients (63.8%) remained on the first DMT. Most treatment switches occurred shortly after approval of a new DMT. Notably, most patients who switched showed no change in motor milestone status between the start of the first and the second DMT. In this large real-world cohort, we present the first comprehensive analysis of SMA treatment patterns across all age groups and disease severities. Although most patients remained on the first DMT, switches were observed, mainly after DMT approvals. Decisions to switch appear multifactorial and are not related directly to motor function effectiveness.

    2026Brain a journal of neurology(2026)
    引用
    AI阅读
    加入学术空间
    5Mapping Mindset: AI-based Psychographic Segmentation Using the Value Map Approach
    Marc Herz, Holger J. Schmidt

    Segmentation based on psychographic criteria, such as values and lifestyles, is essential for effective market development and long-term growth, yet it remains costly, complex, and methodologically demanding in practice. This article introduces an AI-supported approach designed to overcome these challenges. We present the Value Map, an innovative framework that integrates large language models (LLMs) with established psychological value theories to enable scalable customer segmentation based on intrinsic values. The Value Map consists of nearly 500 distinct values that are organized in a structured, interpretable semantic space and can be used to guide and stabilize AI-based analyses of qualitative data. We demonstrate the applicability of this approach using large-scale textual data from thousands of active members of the Porsche Brand Community Rennlist, illustrating how the Value Map enables consistent and meaningful psychographic segmentation at scale. The method is further validated through expert focus groups involving marketing researchers and practitioners, who assess the usability, credibility, and practical relevance of the resulting segments. Overall, the findings advance theoretical understanding of psychographic and value-based segmentation and provide a transparent, AI-enabled tool that enhances the reliability and practical applicability of LLMs in market research and brand strategy.

    2025JOURNAL OF STRATEGIC MARKETING(2025)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 59 篇论文

    合作机构(68)

    Tuscia University合作论文 4
    National Research and Development Institute for Marine Geology and Geoecology合作论文 4
    Muscular Dystrophy Canada合作论文 3
    弗莱堡大学医学院合作论文 3
    杜伊斯堡 - 埃森大学合作论文 3
    Universitätsmedizin Göttingen合作论文 3
    Naturalis Biodiversity Center合作论文 3
    Agricultural Research Council合作论文 3
    英国研究与创新署合作论文 3
    Consorzio Roma Ricerche合作论文 3

    机构统计